Top Markets
#1 Black Phoenix Black Phoenix +734.10%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.03%
#3 TENDIES TENDIES +24.76%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +18.17%
#5 MetaDAO MetaDAO +16.98%
#6 THORChain THORChain +13.86%
#7 Biconomy Biconomy +13.36%
#8 Akedo Akedo +10.89%
#9 THORChain Yield THORChain Yield +10.14%
#10 Bless Bless +9.78%
Coin of the day
Black Phoenix Black Phoenix
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

2315
Clasificación en acciones #4951
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., established in 2009 with its... Biocytogen Pharmaceuticals (Beijing) Co., Ltd., established in 2009 with its main office in Beijing, China, operates as a global biotechnology firm. Its core business involves the international research and development of antibody-based treatments. The company's drug development portfolio currently features a dozen key product candidates; specifically, two are actively progressing through multi-regional Phase II clinical trials, while another pair is in Phase I clinical assessments. Their therapeutic focus spans critical health areas such as oncology, autoimmune disorders, inflammatory conditions, metabolic diseases, and other ailments. Supporting these pharmaceutical ventures, the broader Beijing Biocytogen Co., Ltd. group, which commenced operations in 2008, also in Beijing, specializes in the creation and large-scale distribution of genetically modified animal models. This group provides comprehensive preclinical research services, leveraging its expertise in advanced gene-humanized models, patient-derived xenograft (PDX) models, and human immune system reconstituted models. Their extensive catalog includes a diverse array of specialized gene-edited mice and rats – for example, B-NDG mice, various Cre and knockout (KO) lines (like B-p53 KO and B-ApoE KO), knock-in (KI) models, B-hFcgrt (FcRn) mice, in addition to genome-edited human embryonic stem cells (hESC) and luciferase-reporter stable tumor cell lines. Furthermore, this overarching Biocytogen entity has cultivated an advanced platform dedicated to antibody discovery and development. It offers specialized pharmacology services across vital domains including tumor immunology, general oncology, autoimmune research, and both in vivo and in vitro pharmacological evaluations. The group also makes its products accessible through online sales channels. Beyond its primary location in Beijing, China, the company maintains additional facilities in Haimen, Jiangsu, and Shanghai, China, as well alongside international branches in Heidelberg, Germany, and Boston, United States.
Precio por acción
$7.71
Capitalización bursátil
$3.13B
Cambio (1 día)
-2.82%
Cambio (1 año)
182.84%
País
CN
Comercio Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315)

Categoría

Healthcare
Historial del precio de la acción de Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315)
Precio más alto de cierre: $8.20 el 2026-08-01

Precio más bajo de cierre: $3.28 el 2022-09-01
Historial del precio de la acción de Biocytogen Pharmaceuticals (Beijing) Co., Ltd. desde 2022 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2026 (TTM) 39.60%
2025 307.60%
2024 -32.76%
2023 -56.86%
2022 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $549.38 41.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.05K 47.75%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $148.35 491.02%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.25 -12.92%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $764.47 7.08%
CH